Caffeine interacts with ECHINACEA
The rate at which the body breaks down caffeine may be slowed by echinacea. When used with coffee, echinacea may raise blood levels of the stimulant and raise the possibility of adverse effects such jitteriness, headaches, and rapid heartbeat.
Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with ECHINACEA
The liver modifies and breaks down several drugs. The rate at which the liver breaks down these drugs may change if echinacea is used. The results and side effects of certain drugs may alter as a result.
Medications that decrease the immune system (Immunosuppressants) interacts with ECHINACEA
The immune system’s activity can be boosted by echinacea. Some drugs, such those prescribed after a transplant, reduce the immune system’s function. Echinacea may lessen the effects of several drugs if taken concurrently.
Etoposide (VePesid) interacts with ECHINACEA
Echinacea may slow down the body’s metabolism of etoposide. When used with etoposide, echinacea may make etoposide’s side effects worse.
Midazolam (Versed) interacts with ECHINACEA
The body’s ability to break down midazolam appears to be impacted by echinacea. Echinacea may lessen or intensify the negative effects of midazolam when taken together.
Warfarin (Coumadin) interacts with ECHINACEA
The drug warfarin is used to prevent blood clots. Echinacea may accelerate the breakdown of warfarin and lessen its effectiveness. This could make you more likely to get a clot. Make sure to routinely get your blood tested. Your warfarin dosage may need to be adjusted.
Darunavir (Prezista) interacts with ECHINACEA
Darunavir’s rate of metabolism may be impacted by echinacea. Echinacea may lessen the effects of darunavir or increase the risk of negative effects when taken with it. However, it’s not obvious if this warrants much alarm.
Docetaxel (Taxotere) interacts with ECHINACEA
The rate at which the body breaks down docetaxel may be impacted by echinacea. Echinacea supplementation may lessen the effects of docetaxel or raise the risk of side effects. However, it’s not obvious if this warrants much alarm.
Etravirine (Intelence) interacts with ECHINACEA
The rate at which the body breaks down etravirine may be impacted by echinacea. Echinacea may lessen the effects of etravirine or enhance its negative effects when taken alongside it. However, it’s not obvious if this warrants much alarm.
Lopinavir / Ritonavir (Kaletra) interacts with ECHINACEA
Echinacea may slow down the body’s metabolism of lopinavir and ritonavir. Echinacea can either boost or diminish the effects of lopinavir/ritonavir, depending on whether it is taken alone or in conjunction with it. However, it’s not obvious if this warrants much alarm.
Echinacea with warfarin compatible?
Darunavir (Prezista)
Rating for Interaction: Minor Use this combination with caution. Consult your healthcare practitioner.
To eliminate darunavir (Prezista), the body breaks it down. Echinacea may slow down the body’s absorption of darunavir (Prezista). Echinacea may lessen the effects of darunavir (Prezista) or raise the likelihood of negative effects when taken with it (Prezista). However, no evidence of this in people has been found.
Docetaxel (Docefrez, Taxotere)
Rating for Interaction: Minor Use this combination with caution. Consult your healthcare practitioner.
To eliminate docetaxel (Taxotere), the body breaks it down. The rate at which the body breaks down docetaxel may be impacted by echinacea (Taxotere). Echinacea may reduce the effects of docetaxel (Taxotere) or raise the risk of side effects if taken concurrently with docetaxel (Taxotere). However, no evidence of this in people has been found.
Minor Etravirine (Intelligence) Interaction Use this combination with caution. Consult your healthcare practitioner.
The body modifies and breaks down etravirine (Intelligence). Echinacea may slow down the body’s metabolism of etravirine (Intelence). Echinacea may lessen the effects of etravirine (Intelence) or enhance its negative effects when taken with it (Intelence). But humans have not yet experienced this.
Ritonavir with Lopinavir (Kaletra)
Rating for Interaction: Minor Use this combination with caution. Consult your healthcare practitioner.
The body modifies and breaks down Lopinavir/Ritonavir (Kaletra). Echinacea may slow down the body’s metabolism of lopinavir and ritonavir (Kaletra). Echinacea may either increase or decrease the effects of lopinavir/ritonavir when taken with etravirine (Intelence) (Kaletra). But humans have not yet experienced this.
Midazolam (Versed)
Rating for Interaction: Minor Use this combination with caution. Consult your healthcare practitioner.
The body modifies and degrades midazolam (Versed). It appears that echinacea slows down the body’s metabolism of midazolam (Versed). When used with echinacea, midazolam (Versed) may have more negative side effects or less positive effects (Versed). To understand the effects of echinacea on midazolam, more information is required (Versed).
Coumadin (Warfarin) Interaction Grade: Minor Use this combination with caution. Consult your healthcare practitioner.
Blood clotting is slowed down with warfarin (Coumadin). To eliminate warfarin (Coumadin), the body breaks it down. Echinacea may accelerate the breakdown of warfarin and lessen its effectiveness (Coumadin). Warfarin’s (Coumadin’s) diminished efficiency may raise the chance of clotting. Make sure to routinely get your blood tested. You might need to adjust the warfarin (Coumadin) dosage.
Dosing
FROM MOUTH:
- A 5 mL dose of Echinacea purpurea extract (Echinacin, Madaus AG, Cologne, Germany) taken twice daily for 10 days has been used to treat the common cold. It has also been used to take an extract of Echinacea purpurea called EchinaGuard (Madaus AG, Cologne, Germany), 20 drops in water every two hours on the first day that cold symptoms appear, then three times per day for up to 10 days. It has been used to administer either 5 mL eight times on the first day of cold symptoms, then three times daily for six days, or 4 mL ten times on the first day of cold symptoms of an extract of the entire Echinacea purpurea plant (Echinilin, Inovobiologic Inc., Calgary, Alberta, Canada). On the first day of cold symptoms, drink five or six times a different species of echinacea tea (Echinacea Plus, Traditional Medicinals, Sebastopol, CA), then cut back to one cup per day for the next five days.
- With an increase of 0.9 mL five times day (total dose: 4000 mg daily) at the first indication of a cold, a specialized echinacea extract (Echinaforce, A. Vogel Bioforce AG, Switzerland) has been utilized for the PREVENTION of the common cold.
Report Problems to the Food and Drug Administration
You are urged to inform the FDA of any harmful side effects from prescription medications. Contact FDA MedWatch by phone at 1-800-FDA-1088.
Which herb should be avoided when taking warfarin?
Herbs:
Warfarin should not be taken with the following herbs: garlic, ginger, ginseng, ginkgo, cannabis, dong quai (Angelica sinesis), fenugreek, thyme, oregano, dried basil, alfa alfa, as these herbs enhance the risk of bleeding when combined with warfarin.
While St. John’s wort lessens the effects of the medication, parsley and passion flower enhance the effects of warfarin therapy.
How to Take the Medication –
The medication may be taken once or twice day with food or without food. The effectiveness of the medication may be impacted by a sudden rise or reduction in the consumption of green leafy vegetables. So be sure to regularly eat green leafy vegetables.
Which prescription drugs does echinacea conflict with?
regularly inspected interactions
- Aspirin Extra Mild (aspirin)
- Benadryl (diphenhydramine)
- Calcium/Vitamin D 600 (calcium)
- CoQ10 (ubiquinone)
- Cymbalta (duloxetine)
- fatty fish (omega-3 polyunsaturated fatty acids)
- Garlic Root (ginger)
- ginseng lupulin (ginkgo)
Echinacea cannot be combined with anything.
What foods and medicines should I stay away from while taking echinacea? Avoid anything that contains caffeine, including coffee, tea, cola, energy drinks, and other items. Echinacea can intensify the negative effects of caffeine, including headache, rapid heartbeat, and jitteriness.
In whom should echinacea not be taken?
Consult your doctor before using echinacea if you regularly take other medications. Additionally, if you smoke, use illegal substances, drink alcohol or caffeine-containing beverages, you should disclose this to your doctor. These might impact how echinacea functions.
If you have an autoimmune ailment (like lupus), an infection with the human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome, echinacea may not be beneficial to you (AIDS). Before beginning to use echinacea, you should discuss with your doctor if you are pregnant or nursing.
Echinacea allergy risk may be increased if you have a history of allergies to daisies, ragweed, marigolds, chrysanthemums, or other related plants.
Which anti-inflammatory drugs can I take while taking warfarin?
In this study, we demonstrated that starting NSAIDs in warfarin users could cause a 39.8% patient INR increase. Meloxicam use and warfarin maintenance dosages greater than 40 mg/week made patients more vulnerable to a rise in INR when an NSAID was added.
INR rise was used as the study’s clinical outcome. The typical monitoring technique for warfarin users to foresee bleeding issues is INR measurement (1, 2). Therefore, when NSAIDs are given to patients taking warfarin, rigorous INR monitoring is considered as a viable strategy to reduce bleeding complications (10, 16). Adjusting medication should be seriously examined if INR increases because deadly hemorrhagic complications can occur without any prior mild bleeding.
In this study, we considered an increase in INR of more than 15.0 percent to be noteworthy. INR measurement test variability is known to be 15.0 percent, and this cut-off number was utilized in a different investigation (7). Additionally, our hospital’s PT test variability is less than 2.5 percent. It may be debatable if a 15.0% rise is clinically meaningful. To the best of our knowledge, there isn’t a clear definition of what percentage of an increase in INR is clinically dangerous or safe.
It has not previously been observed that individuals who require high warfarin maintenance dosages are more susceptible to NSAID medication interactions. Warfarin’s increased ability to saturate plasma proteins or metabolic enzymes may be the root of more frequent medication interactions. Another risk factor for INR rise was the coadministration of drugs other than warfarin or NSAIDs. The research population utilized a variety of drugs known to interact with warfarin, as mentioned in the methodology section. As a result, it is reasonable to predict that the presence of coadministered medication will operate as a risk factor. The study population’s heterogeneous comedications may have pleiotropic effects. The outcome of our study, however, mirrors actual clinical situations where patients have a variety of coexisting diseases that call for a variety of treatments. Low INR at baseline was another risk factor for rising INR (P=0.03). This outcome is due to the fact that we used percentage growth rather than absolute growth when defining INR rise.
For the following reasons, however, a cautious approach is required when interpreting the NSAID data. First, we only examined eight different NSAID types. The other seven NSAIDs should be considered when interpreting the findings. Additionally, there were no cases of bleeding with meloxicam in this trial. With early INR increase identification, bleeding might be avoided. If bleeding incidents involving ibuprofen, fenoprofen, and aceclofenac are taken into account, celecoxib or naproxen may be suggested as first-line NSAIDs for people taking warfarin. To support this claim, a prospective investigation including numerous patients is necessary. No matter the class, unless our hypothesis is validated, NSAID addition in warfarin users still requires caution.
In our patient group, abnormal liver function test results were not a risk factor. These findings support a prior study that found mild or moderate hepatic impairment had no impact on how warfarin is disposed of (23). When extrapolating our findings to individuals with severe liver function abnormalities, caution is required because the maximal levels of AST and ALT were within 5 times of the upper range.
The study has a number of restrictions. First, the total number of patients was constrained to allow for a simultaneous evaluation of all potential confounding factors that can influence the INR level. Out of 2,652 applicants, we were only able to recruit 98 patients since INR was rarely assessed following the use of an NSAID. Type I and II interpreting errors could result from the small patient population. Second, although bleeding may be the more clinically significant goal, the study’s endpoint was the INR value, a proxy for hemorrhage. However, clinicians might still have to utilize INR as a guideline when administering warfarin because of the potential severity of bleeding. In this way, clinicians will benefit from our findings.
In conclusion, low baseline INR value, usage of meloxicam, coadministration of medicines, and high maintenance dose of warfarin are the risk factors for INR increase in relation to NSAID-warfarin interaction.
Does taking blood thinners make you less immune?
Date:
Source:
Summary:
According to a recent study, certain viral infections, such as the flu and myocarditis, a viral infection of the heart that is a major cause of sudden death in children and young adults, may become more common and severe while taking a recently approved blood thinner that inhibits a crucial component of the body’s blood clotting system.
Share:
According to a study conducted by scientists at the University of North Carolina, some viral infections, like the flu and myocarditis, which affects the heart and is a major cause of sudden death in children and young adults, may be more common and severe as a result of a recently approved blood thinner that interferes with a crucial component of the body’s blood clotting system.
The anticoagulant medication warfarin has been prescribed for the past 50 years to persons with atrial fibrillation, irregular heartbeats, and other conditions that place them at a higher risk of developing potentially fatal blood clots. The blood thinner Dabigatran etexilate, also known as PradaxaTM, has just received approval from the U.S. Food and Drug Administration for treatment in atrial fibrillation patients. The medication prevents thrombin from acting as the body’s primary activator of the blood clotting mechanism.
The medication disrupts the protease cascade of molecular events that typically takes place in coagulation by inhibiting thrombin activity. The latest study demonstrates that although clot formation is decreased, it may potentially have an unwanted side effect. According to research senior author Nigel Mackman, PhD, the John C. Parker Distinguished Professor of Medicine in the division of hematology and head of the UNC McAllister Heart Institute, “our findings demonstrate that inhibiting thrombin lowers the innate immune response to viral infection.” The risk and severity of the flu and myocarditis may increase with the use of the current generation of blood thinners.
The Journal of Clinical Investigation’s March 2013 issue has a report on the study.
Mackman notes that although the coagulation system is activated by viral diseases like dengue fever, it was once thought to be a harmful thing. Fibrin, the final byproduct of the “clotting cascade” (the process that results in blood clot formation), is said to aid in activating immune cell macrophages, which strengthens the immune system, according to studies on bacterial infections.
However, it appears that the coagulation system’s antiviral mechanism operates through thrombin rather than fibrin, namely through the activation of protease activated receptor proteins like PAR-1, according to Mackman. The purpose of the current study was to determine if PAR-1 contributes to viral infections, a matter that is crucial to the use of PradaxaTM and the creation of antithrombotic medications that target PAR-1 on platelets.
Mackman and colleagues used mice with the PAR-1 gene removed and then exposed them to a myocarditis-causing virus to discover the solution. They discovered that after infection with the cardiotrophic virus, a loss of PAR-1-mediated signaling led to an increase in viral accumulation in the heart, cardiac damage, and eventually, an increase in heart function impairment.
A weaker innate immune response to the virus soon after viral infection was also linked to the absence of PAR-1 signaling. The innate immune system offers early protection against pathogens. Defense comes in almost real-time.
PradaxaTM was administered to healthy mice by the researchers. They demonstrated that thrombin inhibition, which is analogous to a PAR-1 deficiency, enhanced cardiac virus load and heart damage following viral infection. Additionally, they gave the PAR-1-deficient mice influenza A infection and discovered that PAR-1 signaling was crucial for regulating the viral load in the lung during the initial stages of infection. These findings imply that crucial early antiviral signals following infection are mediated by thrombin and PAR-1.
According to Mackman, the drug “PradaxaTM reduces clot formation by lowering fibrin deposition and platelet aggregation.” Importantly, PradaxaTM may interfere with other bodily functions in addition to potentially facilitating major life-saving effects in lowering cardiac mortality.
Our theory was that mice with a PAR-1 deficiency would be protected from viral myocarditis because they would have less inflammation, Mackman continued, adding that the results were absolutely unexpected. “We are currently assessing whether the new blood thinner in general has the same effect on viral infection as the old long-term anticoagulant warfarin or not.”
A number of UNC groups, including those at the Gillings School of Global Public Health, worked together with the Charit — Universittsmedizin in Berlin, Germany, and the Mackman group there to conduct the majority of the study.
Silvio Antoniak, PhD, a postdoctoral researcher in Mackman’s lab, is the first author. A. Phillip Owens III, PhD, Martin Baumnacke, MD, and Julie C. Williams, PhD, were additional co-authors from Mackman’s lab.
Silvio Antoniak received funding for the research from the Myocarditis Foundation. The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health, contributed additional cash.